Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial

Authors:

Abstract
No abstract available
Funding Information
  • TESARO, Inc

This publication has 11 references indexed in Scilit: